-Reuters
HC Wainwright & Co. Assumes Ultragenyx Pharmaceutical at Buy, Announces Price Target of $82
HC Wainwright & Co. analyst Ed Arce assumes Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy rating and announces Price Target of $82.
FOMC: Powell Says Growth Next Year Still Expected To Be Higher Than Potential
-Reuters
Related Posts
Piper Sandler Maintains Neutral on Ally Financial, Lowers Price Target to $47
Piper Sandler analyst Kevin Barker maintains Ally Financial (NYSE:ALLY) with a Neutral and lowers the price target from $54 to $47.
55 Biggest Movers From Friday
Gainers
IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger deal with TeraWulf.